Case Summary: Himalaya Drug Company vs. S.B.L. Ltd (2013)

In this case, Himalaya Drug Company filed a lawsuit against S.B.L. Ltd. for trademark infringement, alleging that S.B.L.’s use of the mark “Liv-T” was deceptively similar to Himalaya’s well-known trademark “Liv.52”. The dispute arose because both marks are used for medicines targeting liver ailments.

Lower Court Decision

The lower court dismissed Himalaya’s lawsuit, reasoning that:

1. The term “LIV” is generic and refers to “liver,” making it non-distinctive and part of the public domain (publici juris).
2. There was no significant similarity between the marks “Liv.52” and “Liv-T”.

High Court Ruling

Himalaya appealed the decision to the Delhi High Court, which overturned the lower court’s judgment. The High Court held that:

1. Onus of Proof on Defendant: The responsibility to prove that “LIV” was a generic term lay with S.B.L. Ltd. The defendant failed to provide sufficient evidence to support this claim.
2. Distinctiveness of ‘LIV.52’: Himalaya demonstrated that “LIV.52” had acquired distinctiveness through extensive usage since 1955, its trademark registration since 1957, and its significant sales over the years.
3. Consumer Recognition: The court noted that customers identified Himalaya’s product as “Liv.52,” indicating that “LIV” was an essential and prominent feature of the trademark.
4. Legal Validity of Trademark: According to Section 32 of the Trade Marks Act, 1958, a registered trademark that has been in use for more than seven years is presumed valid.

Outcome

The High Court concluded that the defendant’s mark “Liv-T” infringed upon Himalaya’s trademark. It restrained S.B.L. Ltd. from using “Liv-T” and directed them to amend their mark to avoid similarity with “Liv.52”.

Significance

This case reinforces the importance of protecting well-established trademarks and clarifies that even seemingly generic terms can gain distinctiveness through prolonged and substantial use in commerce. It also underscores the heavy burden on defendants to prove genericness when challenging a registered trademark.

Ref.: Himalaya Drug Company vs. S.B.L. Ltd. 2013 (53) PTC 1 (Del.) (DB)